NICE

UK & Wales: NICE Recommends First Treatment In Two Decades For Sickle Cell Disease
Clinical News

UK & Wales: NICE Recommends First Treatment In Two Decades For Sickle Cell Disease

For the first time in 20 years, a new therapy for sickle cell disease is to be made available on the UK National Health Service (NHS). Crizanlizumab (Adakveo) by Novartis…
TIF’s Submission To The UK NICE’s Consultation Document For Zynteglo®
News

TIF’s Submission To The UK NICE’s Consultation Document For Zynteglo®

On February 12, in an appraisal consultation document, the UK National Institute for Health and Care Excellence (NICE) recommended against the use of Bluebird Bio’s Zynteglo (betibeglogene autotemcel) gene therapy for the…
Back to top button